REVOLUTION MEDICINES INC. - COMMON STOCK

Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital

01 أغسطس 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Revolution Medicines to Participate in Upcoming Investor Conferences

08 يونيو 2023 16:05:17 بحسب Nasdaq GlobeNewswire

Revolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation Summit

24 مايو 2023 16:05:00 بحسب Nasdaq GlobeNewswire

Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress

08 مايو 2023 16:02:00 بحسب Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023

01 مايو 2023 16:05:37 بحسب Nasdaq GlobeNewswire

Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference

13 أبريل 2023 16:05:40 بحسب Nasdaq GlobeNewswire

Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023

06 أبريل 2023 07:00:54 بحسب Nasdaq GlobeNewswire

Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

07 مارس 2023 16:02:17 بحسب Nasdaq GlobeNewswire

Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock

02 مارس 2023 21:15:55 بحسب Nasdaq GlobeNewswire

Revolution Medicines Announces Commencement of Public Offering of Common Stock

01 مارس 2023 16:17:35 بحسب Nasdaq GlobeNewswire

Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress

27 فبراير 2023 16:05:07 بحسب Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023

21 فبراير 2023 16:05:16 بحسب Nasdaq GlobeNewswire

Revolution Medicines to Participate in Upcoming Investor Conferences

02 فبراير 2023 07:00:12 بحسب Nasdaq GlobeNewswire

Revolution Medicines to Present at 41st Annual J.P. Morgan Healthcare Conference

03 يناير 2023 07:00:01 بحسب Nasdaq GlobeNewswire

Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor

19 ديسمبر 2022 07:00:00 بحسب Nasdaq GlobeNewswire

Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofi’s Termination of SHP2 Inhibitor Development and Commercialization Collaboration

07 ديسمبر 2022 16:05:00 بحسب Nasdaq GlobeNewswire

Revolution Medicines to Participate in Upcoming Investor Conferences

09 نوفمبر 2022 16:05:01 بحسب Nasdaq GlobeNewswire

Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress

07 نوفمبر 2022 16:05:02 بحسب Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022

01 نوفمبر 2022 16:05:00 بحسب Nasdaq GlobeNewswire

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor

22 سبتمبر 2022 07:00:00 بحسب Nasdaq GlobeNewswire